Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 2
2012 1
2014 1
2019 1
2020 2
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer-Härdi U, Caspar CB, Deuster S, Senn M, Winterhalder R, Rochlitz C. Mamot C, et al. Among authors: zurrer hardi u. Sci Rep. 2023 Mar 6;13(1):3705. doi: 10.1038/s41598-023-30950-z. Sci Rep. 2023. PMID: 36879012 Free PMC article. Clinical Trial.
A requirement for p120-catenin in the metastasis of invasive ductal breast cancer.
Kurley SJ, Tischler V, Bierie B, Novitskiy SV, Noske A, Varga Z, Zürrer-Härdi U, Brandt S, Carnahan RH, Cook RS, Muller WJ, Richmond A, Reynolds AB. Kurley SJ, et al. Among authors: zurrer hardi u. J Cell Sci. 2021 Mar 17;134(6):jcs250639. doi: 10.1242/jcs.250639. J Cell Sci. 2021. PMID: 33097605 Free PMC article.
Acceptability and Usability of the Family Gene Toolkit for Swiss and Korean Families Harboring BRCA1/BRAC2 Pathogenic Variants: A Web-Based Platform for Cascade Genetic Testing.
Baroutsou V, Duong V, Signorini A, Saccilotto R, Ciorba FM, Bürki N, Caiata-Zufferey M, Ryu JM, Kim SW, Lim MC, Monnerat C, Zürrer-Härdi U, Kim J, Heinimann K, Graffeo R, Park JS, Rabaglio M, Chappuis PO, Kim S, Katapodi MC, On Behalf Of The Cascade And K-Cascade Consortia. Baroutsou V, et al. Among authors: zurrer hardi u. Cancers (Basel). 2023 Sep 9;15(18):4485. doi: 10.3390/cancers15184485. Cancers (Basel). 2023. PMID: 37760455 Free PMC article.
Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort.
Sarki M, Ming C, Aceti M, Fink G, Aissaoui S, Bürki N, Graffeo R, Heinimann K, Caiata Zufferey M, Monnerat C, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC, The Cascade Consortium. Sarki M, et al. Among authors: zurrer hardi u. J Pers Med. 2022 Oct 19;12(10):1740. doi: 10.3390/jpm12101740. J Pers Med. 2022. PMID: 36294879 Free PMC article.
Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
Sarki M, Ming C, Aissaoui S, Bürki N, Caiata-Zufferey M, Erlanger TE, Graffeo-Galbiati R, Heinimann K, Heinzelmann-Schwarz V, Monnerat C, Probst-Hensch N, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC, On Behalf Of The Cascade Consortium. Sarki M, et al. Among authors: zurrer hardi u. Cancers (Basel). 2022 Mar 23;14(7):1636. doi: 10.3390/cancers14071636. Cancers (Basel). 2022. PMID: 35406409 Free PMC article.
Slug and Sox9 cooperatively determine the mammary stem cell state.
Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell G, Tam WL, Mani SA, van Oudenaarden A, Weinberg RA. Guo W, et al. Among authors: zurrer hardi u. Cell. 2012 Mar 2;148(5):1015-28. doi: 10.1016/j.cell.2012.02.008. Cell. 2012. PMID: 22385965 Free PMC article.
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT. Stoffel ST, et al. Among authors: zurrer hardi u. Swiss Med Wkly. 2021 Mar 1;151:w20464. doi: 10.4414/smw.2021.20464. eCollection 2021 Mar 1. Swiss Med Wkly. 2021. PMID: 33705559 Free article.
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R, Mark M. Ribi K, et al. Among authors: zurrer hardi u. BMC Cancer. 2021 Feb 19;21(1):182. doi: 10.1186/s12885-021-07903-8. BMC Cancer. 2021. PMID: 33607966 Free PMC article.
Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
Kim S, Aceti M, Baroutsou V, Bürki N, Caiata-Zufferey M, Cattaneo M, Chappuis PO, Ciorba FM, Graffeo-Galbiati R, Heinzelmann-Schwarz V, Jeong J, Jung MM, Kim SW, Kim J, Lim MC, Ming C, Monnerat C, Park HS, Park SH, Pedrazzani CA, Rabaglio M, Ryu JM, Saccilotto R, Wieser S, Zürrer-Härdi U, Katapodi MC. Kim S, et al. Among authors: zurrer hardi u. JMIR Res Protoc. 2021 Jun 11;10(6):e26264. doi: 10.2196/26264. JMIR Res Protoc. 2021. PMID: 34114954 Free PMC article.
17 results